CD274 and non-small cell lung carcinoma: In our study, we found that some EGFR-TKI mechanisms may upregulate PD-L1 expression and promote the immune escape ability of EGFR-TKIs resistant NSCLC tumours, but it does not indicate an absolute response to anti-PD-1/PD-L1 therapies.